Form 4: NovoCure Director Sells Shares to Cover Tax Obligations Following RSU Vesting

NovoCure Ltd. Director Martin J. Madden sold 999 ordinary shares at a weighted average price of $17.1928 to satisfy tax withholding obligations related to the vesting of Restricted Stock Units.

Summary

• NovoCure Ltd. Director Martin J. Madden reported a transaction involving the sale of 999 ordinary shares.
• The transaction occurred on June 3, 2025, at a weighted average sale price of $17.1928 per share.
• The sale was executed in multiple trades with prices ranging from $17.1025 USD to $17.50 USD.
• This sale was not a discretionary trade but was mandated by the issuer's award agreement to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs) under the company's equity incentive plans.
• Following this transaction, Martin J. Madden beneficially owns 18,674 ordinary shares directly.

Sentiment

Score: 5

Explanation: The document reports a routine, non-discretionary insider transaction for tax purposes, which is neutral in sentiment as it does not reflect a change in investment conviction.

Management Comments

• The sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary trade by the reporting person.

Stakeholder Impact

• Shareholders: The sale is a non-discretionary event for tax purposes and does not indicate a change in the director's investment outlook or company fundamentals. The impact on share price is likely minimal due to the nature and relatively small volume of the transaction.

Key Dates

Keywords

NovoCure, NVCR, Form 4, SEC filing, insider transaction, share sale, restricted stock units, tax withholding, equity incentive plan, director, beneficial ownership